Overview

Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.

Status:
Terminated

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, multicentre, prospective study of darbepoetin alfa to treat anaemia in patients with low and intermediate-1 IPSS risk MDS. The study will consist of a 14-day screening period followed by a maximum 24-week treatment period and a final visit.

Phase:

Phase 2

Details

Lead Sponsor:

Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon

Treatments:

Darbepoetin alfa